Core Viewpoint - Johnson & Johnson stock is experiencing a rebound after a period of sideways trading, with a notable 43% increase over the past year, and is currently forming a flat base with a buy point of $251.71 [2][4]. Company Performance - Johnson & Johnson's innovative medicines division is projected to contribute 64% of total sales in the first quarter [4]. - The company is set to report its first-quarter earnings on April 14, with analysts expecting adjusted earnings of $2.68 per share on sales of $23.61 billion, indicating a sales growth of nearly 8% despite a projected earnings dip of over 3% [8][9]. Product Developments - Recent studies show that nearly 60% of adolescents with plaque psoriasis achieved clear skin after a year of treatment with the drug Icotyde, with 86% of patients experiencing a 90% reduction in psoriatic lesions [5]. - Johnson & Johnson reported that 89% of patients responded positively to an experimental treatment for bladder cancer and has submitted an application for European approval of Tecvayli for advanced multiple myeloma [6]. - The European Commission approved the prostate cancer pill Akeega, and the FDA granted Fast Track designation to nipocalimab for lupus patients [7]. Market Position - Johnson & Johnson stock has an IBD Composite Rating of 91, indicating it outperforms 91% of all stocks based on fundamental and technical measures [11]. - The stock's relative strength rating is also higher than the broader medical-diversified industry group, which has an RS Rating of 68 [12]. Sales Projections - The company's leading product, Darzalex, is expected to generate $3.85 billion in sales, growing nearly 19%, while Tremfya sales are projected to surge over 49% to $1.43 billion [9][10]. - Medical device sales are anticipated to increase by 6.5% to $8.54 billion [10].

Core Viewpoint - The article emphasizes the importance of investing in defensive stocks amid recent market volatility, highlighting five specific stocks that are well-positioned for stability and growth in uncertain economic conditions [2][4][5]. Group 1: Market Conditions - U.S. stock markets experienced significant volatility in March due to concerns over the sustainability of the AI trade, ongoing geopolitical tensions, rising crude oil and gas prices, inflation expectations, and uncertainty regarding the Federal Reserve's interest rate policy [2]. - The Nasdaq Composite and Dow are in correction territory, trading below 10% from recent highs, while the S&P 500 has recorded its fifth consecutive weekly decline, trading below 8.7% from its recent peak [3]. Group 2: Stock Selection Criteria - Investment in defensive stocks is recommended to safeguard portfolio returns in the near term, focusing on sectors such as utilities, consumer staples, and healthcare [4]. - Stocks selected should be low-beta (beta >0<1) and regularly pay dividends [4]. Group 3: Featured Stocks - **Duke Energy Corp. (DUK)**: Plans to invest $103 billion from 2026-2030 to enhance its grid and expand renewable energy initiatives. DUK has a revenue growth rate of 3.3% and earnings growth rate of 6.3% for the current year, with a dividend yield of 3.28% and a beta of 0.50 [6][10][11]. - **Entergy Corp. (ETR)**: Aims to invest $41 billion from 2026-2029 for infrastructure upgrades and renewable expansion. ETR has a revenue growth rate of 6.8% and earnings growth rate of 12.8% for the current year, with a dividend yield of 2.33% and a beta of 0.64 [12][13]. - **Constellation Brands Inc. (STZ)**: Successfully transitioning to premium brands, with a revenue growth rate of 1.5% and earnings growth rate of 6.5% for the current year, alongside a dividend yield of 2.69% and a beta of 0.44 [14][16]. - **The Coca-Cola Co. (KO)**: Benefits from strong organic revenue growth and effective pricing strategies, with a revenue growth rate of 3.2% and earnings growth rate of 8% for the current year, a dividend yield of 2.80% and a beta of 0.35 [17][19]. - **Johnson & Johnson (JNJ)**: The Innovative Medicine unit shows growth despite exclusivity loss, with a revenue growth rate of 6.6% and earnings growth rate of 7% for the current year, a dividend yield of 2.16% and a beta of 0.34 [20][22].

Core Viewpoint - Royalty Pharma has entered into a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases [1]. Group 1: Agreement Details - The co-funding agreement will support the development of JNJ-4804, an experimental co-antibody therapy targeting IL 23 and TNF, which are immune pathways involved in autoimmune inflammation [2]. - The agreement covers the years 2026 and 2027 [2]. Group 2: Company Insights - Royalty Pharma's CEO, Pablo Legorreta, stated that the drug shows promise for patients with chronic immune-mediated diseases and builds on the company's investments in immunology, including previous medicines targeting TNF [3]. - Royalty Pharma currently receives royalties on over 35 commercial products, including Biogen's Tysabri and J&J's Tremfya, both of which target autoimmune disorders [3].

Core Insights - Royalty Pharma plc has entered into a research and development co-funding agreement with Johnson & Johnson, committing a total of $500 million for the years 2026 and 2027 to support the development of JNJ-4804, a new investigational medicine targeting autoimmune diseases [1][3] Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical sector, collaborating with various entities from academic institutions to leading global pharmaceutical companies [5] - The company has a diverse portfolio that includes royalties on over 35 commercial products, such as Vertex's Trikafta, Johnson & Johnson's Tremfya, and AbbVie and Johnson & Johnson's Imbruvica, among others [5] Product Development - JNJ-4804 is a novel co-antibody therapy that targets both interleukin-23 (IL-23) and tumor necrosis factor (TNF) pathways, aiming to provide synergistic effects in treating chronic immune-mediated diseases [2] - The collaboration with Johnson & Johnson is seen as a strategic opportunity for Royalty Pharma, leveraging its experience in immunology and commitment to partnering with biopharma companies [3]

Core Viewpoint - Johnson & Johnson's Innovative Medicine segment is expected to show growth in Q1 2026, driven by key product sales despite challenges from the loss of exclusivity of Stelara and competitive pressures from biosimilars [1][10]. Sales Performance - The Innovative Medicine unit's sales increased by 4.1% on an organic basis in 2025, even with the loss of exclusivity for Stelara and the negative impact of the Part D redesign [2]. - The segment achieved over $15 billion in sales for three consecutive quarters in 2025, a trend anticipated to continue into Q1 2026 [2]. Key Product Contributions - Growth in Q1 2026 is expected to be supported by increased sales of Darzalex, Tremfya, and Erleada, along with market share gains and expansion [3]. - Newer therapies such as Carvykti, Tecvayli, Talvey, Rybrevant, Lazcluze, Caplyta, and Spravato are also projected to contribute to overall growth [3]. Competitive Landscape - The launch of several biosimilar versions of Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [5]. - Imbruvica sales are expected to decline due to rising competition, and the Part D redesign is anticipated to further affect sales of Stelara, Imbruvica, and Erleada [6]. New Product Developments - Investors are keen on commercialization plans and initial sales figures for newly approved products like Inlexzoh/TAR-200 and Imaavy [7]. - The FDA recently approved Icotyde for treating moderate-to-severe plaque psoriasis, although it will not contribute to Q1 2026 sales [8]. Market Position and Valuation - J&J's shares have outperformed the industry, rising 46.2% over the past year compared to the industry's 10.6% increase [11]. - The company's shares are trading at a forward price/earnings ratio of 20.36, higher than the industry average of 16.99 and above its five-year mean of 15.65 [13]. Earnings Estimates - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, while the estimate for 2027 has increased from $12.33 to $12.44 [15]. - Current estimates for Q1 and Q2 2026 are $2.69 and $2.93 per share, respectively [16].

Core Insights - Johnson & Johnson (J&J) has a robust R&D pipeline focusing on immunology, oncology, and neuroscience, with significant advancements and approvals expected to drive growth through the latter half of the decade [1][10] R&D and Product Approvals - In 2025, J&J received approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis, marking key milestones in its pipeline [1][10] - The FDA approved Icotyde (icotrokinra), an oral treatment for moderate-to-severe plaque psoriasis, co-developed with Protagonist Therapeutics, enhancing J&J's portfolio [2][4] - Inlexzoh is a novel drug-releasing system for bladder cancer, while nipocalimab is being evaluated for various immune-mediated conditions, indicating its potential as a versatile treatment option [3][5] Market Potential and Sales Growth - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $3 billion in sales in 2025, contributing to overall revenue growth [6][10] - The company anticipates that 10 of its new products could achieve peak sales of $5 billion, with expectations for a more significant impact from new products in 2026 compared to 2025 [7][8] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 47.1% over the past year compared to the industry's 9.5% increase [11] - The company's shares are currently trading at a price/earnings ratio of 20.42, higher than the industry average of 16.75, indicating a slightly expensive valuation [12] - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, with a slight increase for 2027 earnings from $12.33 to $12.44 [13][14]

Core Insights - Johnson & Johnson's stock has shown strong performance, remaining above its 50-day and 200-day simple moving averages for over eight months, indicating sustained investor confidence [1] - The stock formed a "golden cross" in July, suggesting a potential for a prolonged bullish trend, supported by improving business performance [1] Sales and Earnings Growth - J&J's share price performance is driven by steady growth in sales and earnings, particularly from the Innovative Medicine and MedTech segments, with an optimistic outlook for 2026 [2] - The Innovative Medicine segment saw a 4.1% organic sales growth in 2025, despite the loss of exclusivity for Stelara, with key drugs like Darzalex, Erleada, and Tremfya contributing significantly [4][5] - The segment achieved over $60 billion in full-year sales in 2025, with 13 brands growing in double digits [5] Pipeline and R&D Investments - J&J invested over $32 billion in R&D and M&A in 2025, including acquisitions that enhance its product portfolio [10] - Significant pipeline advancements were made in 2025, with new product approvals expected to drive growth in 2026 [11][12] - J&J believes that several new products have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, and Imaavy [14] MedTech Segment Performance - The MedTech segment improved sales by 4.3% on an organic basis in 2025, driven by acquisitions and advancements in various product lines [15] - J&J anticipates better growth in the MedTech business in 2026, despite facing challenges in the Chinese market due to government cost containment efforts [16][17] Challenges and Risks - The loss of U.S. patent exclusivity for Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [18][19] - J&J faces over 74,000 lawsuits related to its talc-based products, which could pose significant legal and financial challenges [21][22] Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 46.2% over the past year compared to a 7.5% increase in the industry [23] - The stock is currently trading at a price/earnings ratio of 20.05, higher than the industry average of 16.69, indicating a slightly expensive valuation [27] Future Outlook - The Zacks Consensus Estimate for 2026 earnings has increased, reflecting positive sentiment around J&J's growth prospects [30] - J&J aims to generate around $100 billion in revenues in 2026, with expectations for sales growth in both segments to be higher than in 2025 [34] - Despite facing headwinds, J&J remains confident in navigating challenges and maintaining strong momentum [34][35]

Core Insights - Royalty Pharma plc has appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026, to enhance its AI capabilities across the organization [1][2] - The appointment is part of Royalty Pharma's strategy to integrate advanced technology, including intelligent automation and AI-driven decision support, to improve investment evaluations and operational efficiency [2] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector [3] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, and has a portfolio that includes royalties on over 35 commercial products and 19 development-stage candidates [3]

Core Insights - Protagonist Therapeutics (PTGX) shares have increased nearly 7% following the FDA approval of icotrokinra, developed in partnership with Johnson & Johnson (JNJ), for treating moderate-to-severe plaque psoriasis in patients aged 12 and older [1][6] FDA Approval and Product Details - Icotrokinra, marketed as Icotyde in the U.S., is the first targeted oral peptide designed to inhibit the IL-23 receptor [2][4] - The FDA approval was supported by data from four phase III studies within the ICONIC program, demonstrating significant skin clearance and a favorable safety profile [4] Financial Implications - Protagonist will receive a $50 million milestone payment from JNJ, with potential for up to $580 million more in regulatory and sales-based milestones [6][7] - Protagonist is entitled to tiered royalties on global net sales, ranging from 6% to 10%, with an average of approximately 7.25% at $4 billion in annual sales [7] Market Potential - JNJ believes Icotyde has the potential to revolutionize plaque psoriasis treatment as a once-daily oral alternative to existing injectables [8] - Icotyde is also being evaluated for other indications, including psoriatic arthritis and inflammatory bowel diseases, indicating broader market potential [9]

Core Insights - Johnson & Johnson (JNJ) has made significant advancements in its pipeline, achieving key clinical and regulatory milestones that are expected to drive growth through the latter half of the decade [1] - The company received approvals for new products, including Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [1] Product Approvals and Pipeline - Inlexzoh is a novel drug-releasing system that allows for sustained local delivery of cancer treatment directly into the bladder [2] - Nipocalimab, an FcRn blocker, is under review for multiple immune-mediated conditions, including warm autoimmune hemolytic anemia and systemic lupus erythematosus, with potential for significant market impact [2] - In 2026, J&J and Protagonist Therapeutics received FDA approval for icotrokinra (marketed as Icotyde), an oral targeted peptide inhibitor for moderate-to-severe plaque psoriasis [3][10] - Icotyde's approval was based on data from four phase III studies, demonstrating significant skin clearance and a favorable safety profile [4] - Icotyde is expected to revolutionize plaque psoriasis treatment by offering a once-daily oral option, contrasting with existing injectable treatments [5][6] Market Potential - J&J anticipates that Inlexzoh, Icotyde, and Imaavy are among ten new drugs that could collectively achieve peak sales of $5 billion [7] - The company expects a more pronounced impact from new products in 2026 compared to 2025, highlighting the strength of its late-stage pipeline [8] Financial Performance - JNJ's shares have outperformed the industry, rising 45.6% over the past year compared to an 8.0% increase in the industry [9] - The company's shares currently trade at a price/earnings ratio of 20.23, higher than the industry average of 17.25, indicating a slightly expensive valuation [11] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.46 to $11.54, while the estimate for 2027 has risen from $12.25 to $12.44 [12]